Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306150 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy
A Phase 3 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 57
- Enrollment target
NCT00306150 is a Phase 3 study that was terminated before completion, run by Bayer. The registered enrollment target is 57 participants.
The verdict
NCT00306150, a Phase 3 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to assess if aprotinin (BAYA0128), given intravenously during your surgery, is safe and can help reduce the need for a blood transfusion during bladder surgery.
Interventions
- DRUG Placebo
- DRUG Trasylol (Aprotinin, BAYA0128)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306150
The ClinicalTrials.gov registry entry for NCT00306150 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00306150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306150 about?
NCT00306150 is a clinical study titled "Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy". The purpose of this study is to assess if aprotinin (BAYA0128), given intravenously during your surgery, is safe and can help reduce the need for a blood transfusion during bladder surgery.
What is the current status of trial NCT00306150?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 57 participants. The study started on 2005-12. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00306150?
The interventions under investigation include: Placebo (DRUG), Trasylol (Aprotinin, BAYA0128) (DRUG).
Who is sponsoring clinical trial NCT00306150?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.